We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Successful management of malignant hyperthermia without dantrolene in paediatric anaesthesia.
- Authors
Menasri, Sami; Slimani, Rabie; Grainat, Nadia; Brinis, Nejma; Bourenane, Haithem; Zerizer, Yacine
- Abstract
Malignant hyperthermia is a rare inherited disorder that develops following exposure to volatile anaesthetic agents and depolarising muscle relaxants. The overall incidence of malignant hyperthermia during general anaesthesia is estimated to range from 1 in 5000 to 1 in 50,000-100,000 and the mortality rate is estimated to be < 5% in the presence of standard care. In Algeria, this incidence is even lower because of the absence of the succinylcholine second triggering agent, but there is no centre where an in vitro caffeine- halothane contracture test is performed to confirm the diagnosis in suspected cases. The drug of choice for this condition, dantrolene, is not freely available in Algeria. We hereby report the case of a 7-year-old boy who had previously undergone uneventful general anaesthesia. He developed malignant hyperthermia and survived the condition despite the non-availability of dantrolene, emphasising the role of early detection and aggressive management in these cases. Survival without dantrolene remains exceptional, especially in paediatric cases (there are few cases in the recent literature). This is probably the first case report of this disease from Algeria.
- Subjects
ALGERIA; INDUCED hypothermia; PROPOFOL; ROCURONIUM bromide; PEDIATRIC anesthesia; GENERAL anesthesia; BODY temperature; INTRAOPERATIVE care; TESTICULAR diseases; FENTANYL; CREATINE kinase; MALIGNANT hyperthermia; SEVOFLURANE; INTRAOPERATIVE monitoring; EARLY diagnosis; TRACHEA intubation; CAPNOGRAPHY; CHILDREN
- Publication
Update in Anaesthesia, 2019, Vol 33, p70
- ISSN
1353-4882
- Publication type
Article